Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384520189> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4384520189 endingPage "224" @default.
- W4384520189 startingPage "216" @default.
- W4384520189 abstract "Background and objective. Rheumatoid arthritis (RA) is a chronic and inflammatory disease affecting millions of people and making an enormous economic impact. The healthcare coverage for RA in Mexico is limited and the biologic drugs are conditioned to mild or severe disease, or to failure or inappropriate response to the conventional synthetic disease-modifying antirheumatic drugs (DMARDcs). The objective of this article was to determine whether if there is enough evidence supporting the efficacy of tocilizumab (TCZ) as the first-line treatment for RA, administered as monotherapy or in combination with DMARDcs. Material and Methods. A rheumatology expert group conducted a systematic review of the literature in order to analyze the efficacy and safety of TCZ as a biologic DMARD in combination with DMARDcs and as monotherapy in patients with RA. The group used the search strategy known as 6S for evidence-based medicine. Results. A total of 44 articles were analyzed. For clinical evidence, we found randomized controlled trials (RCT) showing more significant benefit in the groups, which received TCZ alone or in combination, according to the evaluation made with clinimetric tools. These six trials had at least a 52-week follow-up (up to 260 weeks) and included 3,413 subjects. Two RCT —including 1,479 patients— identified that the most frequent adverse event was rhinopharyngitis. Discussion. There is enough evidence to suggest that TCZ may be administered in patients with failure to biologics or as a first-line treatment, both in combination with methotrexate (MTX) (or other drugs) and in intravenous or subcutaneous monotherapy. TCZ is an effective and applicable alternative for the Mexican population in first line and in failure to DMARD, with or without MTX." @default.
- W4384520189 created "2023-07-18" @default.
- W4384520189 creator A5005429757 @default.
- W4384520189 creator A5037312155 @default.
- W4384520189 creator A5038765430 @default.
- W4384520189 creator A5056841718 @default.
- W4384520189 creator A5058290026 @default.
- W4384520189 creator A5062401640 @default.
- W4384520189 creator A5078436083 @default.
- W4384520189 creator A5085844513 @default.
- W4384520189 date "2020-10-28" @default.
- W4384520189 modified "2023-09-27" @default.
- W4384520189 title "Uso de tocilizumab en artritis reumatoide en México" @default.
- W4384520189 doi "https://doi.org/10.34141/ljcs1181908" @default.
- W4384520189 hasPublicationYear "2020" @default.
- W4384520189 type Work @default.
- W4384520189 citedByCount "0" @default.
- W4384520189 crossrefType "journal-article" @default.
- W4384520189 hasAuthorship W4384520189A5005429757 @default.
- W4384520189 hasAuthorship W4384520189A5037312155 @default.
- W4384520189 hasAuthorship W4384520189A5038765430 @default.
- W4384520189 hasAuthorship W4384520189A5056841718 @default.
- W4384520189 hasAuthorship W4384520189A5058290026 @default.
- W4384520189 hasAuthorship W4384520189A5062401640 @default.
- W4384520189 hasAuthorship W4384520189A5078436083 @default.
- W4384520189 hasAuthorship W4384520189A5085844513 @default.
- W4384520189 hasConcept C126322002 @default.
- W4384520189 hasConcept C168563851 @default.
- W4384520189 hasConcept C1862650 @default.
- W4384520189 hasConcept C197934379 @default.
- W4384520189 hasConcept C198451711 @default.
- W4384520189 hasConcept C2776999253 @default.
- W4384520189 hasConcept C2777178219 @default.
- W4384520189 hasConcept C2777575956 @default.
- W4384520189 hasConcept C2781059491 @default.
- W4384520189 hasConcept C2908564923 @default.
- W4384520189 hasConcept C2909063479 @default.
- W4384520189 hasConcept C535046627 @default.
- W4384520189 hasConcept C71924100 @default.
- W4384520189 hasConceptScore W4384520189C126322002 @default.
- W4384520189 hasConceptScore W4384520189C168563851 @default.
- W4384520189 hasConceptScore W4384520189C1862650 @default.
- W4384520189 hasConceptScore W4384520189C197934379 @default.
- W4384520189 hasConceptScore W4384520189C198451711 @default.
- W4384520189 hasConceptScore W4384520189C2776999253 @default.
- W4384520189 hasConceptScore W4384520189C2777178219 @default.
- W4384520189 hasConceptScore W4384520189C2777575956 @default.
- W4384520189 hasConceptScore W4384520189C2781059491 @default.
- W4384520189 hasConceptScore W4384520189C2908564923 @default.
- W4384520189 hasConceptScore W4384520189C2909063479 @default.
- W4384520189 hasConceptScore W4384520189C535046627 @default.
- W4384520189 hasConceptScore W4384520189C71924100 @default.
- W4384520189 hasIssue "1" @default.
- W4384520189 hasLocation W43845201891 @default.
- W4384520189 hasOpenAccess W4384520189 @default.
- W4384520189 hasPrimaryLocation W43845201891 @default.
- W4384520189 hasRelatedWork W189077404 @default.
- W4384520189 hasRelatedWork W1987294331 @default.
- W4384520189 hasRelatedWork W2049114537 @default.
- W4384520189 hasRelatedWork W2098703756 @default.
- W4384520189 hasRelatedWork W2736593664 @default.
- W4384520189 hasRelatedWork W2766107824 @default.
- W4384520189 hasRelatedWork W2794029630 @default.
- W4384520189 hasRelatedWork W2948566177 @default.
- W4384520189 hasRelatedWork W2996380604 @default.
- W4384520189 hasRelatedWork W4239841759 @default.
- W4384520189 hasVolume "2" @default.
- W4384520189 isParatext "false" @default.
- W4384520189 isRetracted "false" @default.
- W4384520189 workType "article" @default.